Pharmacy Times
JULY 18, 2022
Patients with diabetes on Medicare Advantage were also less likely to be prescribed newer, more expensive medicine than patients on Medicare Fee-For-Service plans, indicating potential disparities in care.
pharmaphorum
JULY 18, 2022
GSK’s consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion). The new company – which has achieved the largest London listing in a decade – has annual sales of around £10 billion from brands like Sensodyne toothpaste, Voltaren and Panadol painkillers, and Centrum multivitamins, making it the second-largest consumer health company in the world.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 18, 2022
A study demonstrated the role of the serotonin 1B receptor in appetite and showed that triptan, a commonly prescribed migraine medicine, may be repurposed for appetite suppression and obesity.
pharmaphorum
JULY 18, 2022
As you know, clinical trials can be complex. Industry standards are now required for clinical trial submission. This means even more associated costs, resources, time, and effort. The Formedix clinical metadata repository ( MDR ) can help! So what can it do for you? In a nutshell, it can help you: How is this possible? Take studies and standards for example.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
JULY 18, 2022
Use of these drugs as medications, though, promising, may be restricted for various reasons to a select few.
PharmaVoice
JULY 18, 2022
The pandemic has forced the pharmaceutical industry to look at digital in a new way - and it’s driving better health outcomes
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
European Pharmaceutical Review
JULY 18, 2022
Grünenthal has agreed to acquire testosterone treatment Nebido TM and its associated brands from Bayer AG, for up to €500 million. The long-acting injectable treatment for testosterone deficiency has been commercially approved in more than 80 countries. Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States.
Pharmacy Times
JULY 18, 2022
Ryan Burke, PharmD, director of professional affairs at Pharmacy Technician Certification Board, discusses how the changing role of pharmacy technicians has also helped the role of the pharmacist.
European Pharmaceutical Review
JULY 18, 2022
Treatment with both higher and lower doses of Dupixent ® (dupilumab) resulted in histological disease remission at 16 weeks in children aged one to 11 years with eosinophilic oesophagitis (EoE) – achieving the Phase III trial’s primary endpoint. EoE is a chronic inflammatory disease that damages the oesophagus and prevents it from functioning properly.
Pharmacy Times
JULY 18, 2022
Tildrakizumab-asmn is a humanized IgG1/k monoclonal anti-IL-23 antibody indicated for the treatment of adults with moderate-to-severe plaque psoriasis.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Technology
JULY 18, 2022
Quoin Pharmaceuticals and Endo International subsidiary Endo Ventures have signed a licence and distribution agreement and a supply agreement to develop, register, supply, market and distribute the former’s QRX003 exclusively in Canada. A lead product of Quoin, QRX003 is a topical lotion intended to treat Netherton Syndrome. As per the terms of the license and distribution deal, Endo holds the exclusive right, which was also sublicensed to the affiliate of the company, Paladin Labs, to market th
Pharmacy Times
JULY 18, 2022
It's really important that we capitalize on this time and the impact that pharmacists had to make some of this reform permanent.
Pharmaceutical Technology
JULY 18, 2022
GlaxoSmithKline (GSK) has signed an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to aid in protecting adults and children in the country. Spanning to March 2026, the four-year agreement comprises the delivery of nearly 80 million doses of adjuvanted pandemic influenza vaccine, Arepanrix, and at least four million doses of seasonal influenza vaccine, Flulaval Tetra, each year.
Pharmacy Times
JULY 18, 2022
Health system specialty pharmacies help remove barriers to care, optimize therapy, and improve outcomes.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmaceutical Technology
JULY 18, 2022
The European Commission (EC) has granted conditional marketing authorization (CMA) for Calliditas Therapeutics’ Kinpeygo to treat primary immunoglobulin A (IgA) nephropathy (IgAN) in adults. The treatment is indicated for IgAN patients at risk of quick disease progression risk with a urine protein-to-creatinine ratio (UPCR) ?1.5g/gram. . An orphan medicinal product, Kinpeygo is the first and only therapy to receive approval for IgAN.
Pharmacy Times
JULY 18, 2022
Building a team to support best practices, medication safety, and staff education will reduce risks.
Pharma Tutor
JULY 18, 2022
Drug Regulatory Affairs Certificate Institutes in India. Historical Overview of Pharmaceutical Industries and Regulatory Affairs:During 1950s, multiple tragedies i.e., sulfanilamide elixir, vaccine tragedy and thalidomide tragedy have resulted in substantial increase of legislations for drug products quality, safety and efficacy. This has also resulted into stricter norms for Marketing Authorization (MA) and Good Manufacturing Practices (GMPs). admin.
Pharmacy Times
JULY 18, 2022
Influenza viruses typically circulate in the Northern Hemisphere during the winter and spring, but they occasionally can circulate more during the summer months, as did the 2009 H1N1 pandemic strain.
Pharmaceutical Technology
JULY 18, 2022
Bronchiectasis is defined by the permanent and abnormal damage to the bronchi, causing dilation and scarring, and usually occurs in the context of chronic airway infection and inflammation, often with thick and difficult-to-clear mucus. Bronchiectasis occurs across age groups but is most prevalent in adults and more common in females. Symptoms vary from excessive coughing, chest discomfort, and even weight loss, exacerbating other symptoms such as breathlessness.
Pharmacy Times
JULY 18, 2022
Red Cross Canker Sore Medication is used for temporary relief of pain and minor irritation of the mouth and gums due to sores, minor dental procedures, braces, and dentures.
pharmaphorum
JULY 18, 2022
Byondis has filed its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the US and Europe, setting up possible approvals next year and a showdown with heavyweight competitors Roche and AstraZeneca/Daiichi Sankyo. The Dutch biotech submitted the ADC to the FDA last week and said this morning the EMA had formally started its review of the drug for HER2-positive, locally advanced or metastatic breast cancer that can’t be treated with surgery.
Pharmacy Times
JULY 18, 2022
Phase 3 study follows recent approval of the drug for the same condition in individuals aged 12 years and older who weight at least 40 kg.
Outsourcing Pharma
JULY 18, 2022
A pediatric clinical trial expert from the CRO discusses the unique challenges involved in designing a study when the patients involved are little ones.
Pharmacy Times
JULY 18, 2022
Patients with heart failure in bereavement are at a higher risk of death from the condition, particularly in the first week following a family member’s death.
Aureus Medical Group
JULY 18, 2022
From intake to housing arrangements, it can take anywhere from two to five weeks for a new traveler to start their very first travel assignment. There are so many factors that play into this timeline, and the more you travel, the quicker the process becomes. Seasoned Aureus Medical Group travelers have applied for an assignment, interviewed, and set up housing arrangements in as little as one day!
Pharmacy Times
JULY 18, 2022
Persistence by pharmacists and showing patients respect can help overcome misinformation.
The Guardian - Pharmaceutical Industry
JULY 18, 2022
Consumer health company ends first day on London Stock Exchange with £28.5bn market valuation Opinion: Haleon may not be the jewel in GSK’s medicine cabinet GSK’s consumer spin-off Haleon, home to brands from Sensodyne toothpaste to Panadol painkillers, has begun trading on the London Stock Exchange in the biggest European listing in a decade. Haleon shares started trading on Monday morning at 330p, with a market value of about £31bn, but at the end of day one it was £28.5bn.
Pharmacy Times
JULY 18, 2022
Apomorphine (Kynmobi) is indicated for the acute, intermittent treatment of off episodes in patients with Parkinson disease.
Oswald's
JULY 18, 2022
It can be tough to find solutions for strains and stress that don’t include some sort of medication. Stress, both mental & physical, can be a huge detriment to your daily life, one that you may be using OTC medications to relieve.* We have been looking for all-natural solutions to add comfort to everyday problems… The post All-Natural Solutions for Comfort appeared first on Oswald's Pharmacy.
Pharmacy Times
JULY 18, 2022
Data from Roche’s phase 3 HAVEN 6 study show clinically meaningful bleed control, with no new safety signals observed.
pharmaphorum
JULY 18, 2022
UK startup Oto has raised £2.8 million ($3.3 million) in seed financing for a mobile app that aims to help people with tinnitus manage the ringing, buzzing or other noises in their ears that can wreak havoc with their quality of life. The app doesn’t promise to treat tinnitus – in fact there are no approved therapies for the condition, which affects one in seven people worldwide.
Pharmacy Times
JULY 18, 2022
Maker of Sensodyne, Advil, and TUMS becomes one of the world’s leading independent consumer health companies.
Pharmaceutical Technology
JULY 18, 2022
The proportion of pharmaceutical companies hiring for data analytics related positions rose in June 2022 compared with the equivalent month last year, with 70.1% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 65% of companies who were hiring for data analytics related jobs a year ago and an increase compared to the figure of 67.8% in May 2022.
pharmaphorum
JULY 18, 2022
AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up with main rivals Pfizer/BioHaven and their recently-approved Vydura drug. The EMA filing for atogepant covers the prevention of migraine in adults who have at least four migraine days per month – the same indication that was approved for Vydura (rimegepant) in April as it became the first oral drug for prophylaxis of the debilitating condition.
Expert insights. Personalized for you.
139 
Let's personalize your content